OVARIAN CANCER and US: A weekly topotecan and biweekly bevacizumab combination demonstrates acceptable toxicity and encouraging efficacy in patients with platinum-resistant

OVARIAN CANCER and US

An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.

“Not everything that can be counted counts and not everything that counts can be counted.”

Albert Einstein

Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Saturday, August 06, 2011

A weekly topotecan and biweekly bevacizumab combination demonstrates acceptable toxicity and encouraging efficacy in patients with platinum-resistant

Note: pay particular attention to the side effects/adverse events

OvarianCancerandUs

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.

View web version

Sandi Pniauskas Ovarian Cancer and Us

OvarianCancerandUs

View my complete profile

Powered by Blogger.